Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics
Applied Biosciences · 05.03.2025 · 4 (1) · 16
DOI: 10.3390/applbiosci4010016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Biosciences, online erschienen am 05.03.2025. Verfasst von Abdurraouf Mokhtar Mahmoud und 1 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy, AIL Novara VCO ODV, Italy.
Abstract (Originalsprache)
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, pose significant therapeutic challenges due to their heterogeneity and high relapse rates. Nanotechnology has emerged as a promising avenue for precision drug delivery in these malignancies, allowing for enhanced drug concentration at tumor sites and reducing systemic toxicity. Recent developments in nanocarriers—such as liposomes, polymeric nanoparticles, and inorganic nanoparticles—have enabled targeted approaches, utilizing molecular markers specific to malignant cells to increase therapeutic efficacy while minimizing adverse effects. Evidence from preclinical and clinical studies underscores the potential of nanotechnology to improve patient outcomes by facilitating controlled release, improved bioavailability, and reduced toxicity. However, translating these advancements into clinical practice requires further research to validate their safety and efficacy. This review provides a comprehensive analysis of the latest innovations in nanotechnology for targeted drug delivery in hematologic malignancies, addressing current achievements and future directions for integrating these approaches into Clinical Hemato-Oncology.
Förderung
- Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy
- AIL Novara VCO ODV, Italy
Zitieren
APA
Mahmoud, A. M., & Deambrogi, C. (2025). Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics. Applied Biosciences, 4(1), 16. https://doi.org/10.3390/applbiosci4010016
Vancouver
Mahmoud AM, Deambrogi C. Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics. Applied Biosciences. 2025;4(1):16. doi:10.3390/applbiosci4010016
BibTeX
@article{Mahmoud2025,
author = {Mahmoud, Abdurraouf Mokhtar and Deambrogi, Clara},
title = {Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics},
journal = {Applied Biosciences},
year = {2025},
volume = {4},
number = {1},
pages = {16},
doi = {10.3390/applbiosci4010016}
}
EUVIMED